ATM and hepatocellular carcinoma: Accordingly, the selective ATM inhibitor KU-55933 markedly reduces the AMPKα-activating effects of metformin in rat hepatoma cells, functionally supporting the first genome-wide association study that unexpectedly found the ATM gene as the causal modulator of glycemic responsiveness to metformin among type 2 diabetic patients [8].